Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global expansion of Biosolution’s cartilage cell therapeutics, CartiLife (expecting Korea FDA approval in 2019), and how their human tissue model could replace animal testing.
There are a lot of players looking to enter this market, and cell therapeutics are among the most advanced areas within regenerative medicines.
